# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao reiterates argenx (NASDAQ:ARGX) with a Buy and maintains $448 price target.
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.
Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the price target from $5...
JP Morgan analyst James Gordon maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the price target from $560 to $500.
HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and lowers the price target from $451...
JMP Securities analyst Jason Butler maintains argenx (NASDAQ:ARGX) with a Market Outperform and lowers the price target from...